key: cord-1036691-vfqoryy0 authors: Sama, Iziah E; Voors, Adriaan A title: Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes date: 2020-08-21 journal: Eur Heart J DOI: 10.1093/eurheartj/ehaa527 sha: 57d9dea7b13585c9506145b83e45cdb305efe46d doc_id: 1036691 cord_uid: vfqoryy0 nan In the commentary entitled 'Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease', Schmidt et al. 1 corroborate our work on plasma angiotensin-converting enzyme 2 (ACE2) levels in heart failure patients 2 by extending it to patients with kidney diseases. They did this by measuring plasma ACE2 levels from 551 patients in the Boston Kidney Biopsy Cohort 3 and came to similar conclusions that (i) higher plasma ACE2 is observed in men than women; (ii) in those with diabetes; and (iii) do not appear to be increased by use of angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACE-I/ARB). Interestingly, it is now known that the use of ACE-I/ARB is not positively associated with mortality in COVID-19 patients. 4 In a sub-analyses wherein we pooled both cohorts of our study, male sex, renal disease, diabetes, blood glucose, and glycated HbA1c were significantly more predominant (P < 0.05) in the group of patients with elevated (> _median) compared to low (